WO1998037240A1 - Anti-sense oligonucleotide pharmacological agents - Google Patents
Anti-sense oligonucleotide pharmacological agents Download PDFInfo
- Publication number
- WO1998037240A1 WO1998037240A1 PCT/US1998/003636 US9803636W WO9837240A1 WO 1998037240 A1 WO1998037240 A1 WO 1998037240A1 US 9803636 W US9803636 W US 9803636W WO 9837240 A1 WO9837240 A1 WO 9837240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sense
- subject
- oligonucleotides
- ohgonucleotide
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
Definitions
- Antisense therapy involves the administration of exogenous oligonucleotides that bind to a target nucleic acid, typically an RNA molecule, located within cells.
- a target nucleic acid typically an RNA molecule
- the term antisense is so given because the oligonucleotides are typically complementary to mRNA molecules ("sense strands") which encode a cellular product.
- mRNA molecules mRNA molecules
- anti-sense oligonucleotides to inhibit expression of mRNAs, and thereby to inhibit protein expression in vivo, is well documented.
- selection of an appropriate complimentary ohgonucleotide (or oligonucleotides) to a given mRNA is not always simple (see, e.g., Crooke, S.T. FASEB J.
- Anti-sense agents typically need to continuously bind all target RNA molecules so as to inactivate them or alternatively provide a substrate for endogenous ribonuclease H (Rnase H) activity. Sensitivity of RNA/oligonucleotide complexes, generated by the methods of the present invention, to Rnase H digestion can be evaluated by standard methods (see, e.g., Donia, B. P., et al., J. Biol. Chem. 268 (19):14514-14522 (1993); Kawasaki, A. M, et al., J. Med. Chem.
- Anti-sense oligonucleotides which are as long as the entire mRNA compliment have been used to modulate mRNA translation, but have disadvantages associated with large sequences, e.g., pharmacological availability.
- long oligonucleotides may have less ability to discriminate between target sequences which differ in only one (or a few positions).
- Shorter anti-sense oligonucleotides may be more bioavailable or more easily formulated, and can generally be synthesized by chemical methods more easily than can longer sequences. However, shorter oligonucleotides must be selected to have sufficient stability to hybridize to the target nucleic acid in vivo, and must also have sufficient length to bind selectively to the target sequence, while avoiding excessive binding to non-target sequences.
- the present invention relates to anti-sense therapy, e.g., for disease management or eradication.
- the invention further relates to methods for selecting tandem oligonucleotides for use as anti-sense agents in vivo or in vitro.
- the invention provides a method of treating a condition related to expression of mRNA, comprising administering to a subject in need thereof an effective amount of a first anti-sense ohgonucleotide complementary to a first region of a target mRNA sequence and a second anti-sense ohgonucleotide complementary to a second mRNA sequence, the first and second anti-sense regions of the target mRNA sequence being substantially contiguous, such that the condition is treated.
- the target mRNA sequence is a mutant sequence, i.e., a sequence which differs from a normal or wild-type nucleic acid sequence by one or more nucleotide bases.
- the first and second anti-sense oligonucleotides are selected such that the first and second anti-sense oligonucleotides can hybridize to the target (e.g., mutant) sequence while not significantly hybridizing to the target (e.g., native or wild-type) sequence, such that selective therapy is provided.
- the invention provides a method for providing tandem antisense oligonucleotides for use in anti-sense therapy.
- the method includes the steps of selecting first and second regions of a target nucleic acid sequence (e.g., of a subject organism), the first and second regions being substantially contiguous; and preparing first and second anti-sense oligonucleotides, the first anti-sense ohgonucleotide being complementary to the first region of the target nucleic acid sequence, and the second anti-sense ohgonucleotide being complementary to the second region of the target nucleic acid sequence, such that tandem anti-sense oligonucleotides are provided.
- a target nucleic acid sequence e.g., of a subject organism
- At least one of the first and second antisense oligonucleotides is perfectly complementary to a respective region of a mutant nucleic acid sequence of an organism, but is not perfectly complementary (e.g., at one or more base positions) to a normal or wild-type nucleic acid sequence of an organism.
- the invention provides a method for discriminating between two different target RNA molecules whose sequences differ by a single base.
- the invention could be used to preferentially inhibit those cells containing a single base variant of a virus while allowing cells without the single base change virus variant to not be inhibited.
- kits comprising tandem anti-sense oligonucleotides in a container, preferably with instructions for using the tandem antisense oligonucleotides in a therapeutic method.
- the invention provides tandem anti-sense oligonucleotides in a pharmaceutically acceptable carrier.
- the invention provides a method of treating a subject suffering from a disorder, where the disorder is characterized by the presence of a mutation in at least one portion of gene, comprising administering to the subject in need thereof, an effective amount of first and second oligonucleotides which bind to substantially contiguous sites of the mutant form of the gene while substantially not binding to the normal form of the gene.
- the invention provides a method of treating a subject with a disorder, wherein the disorder is characterized by the presence of a mutation in a nucleic acid sequence of the subject (e.g., an mRNA sequence of the subject), comprising administering to a subject in need thereof, an effective amount of at least two oligonucleotides which bind cooperatively to the mutant gene, such that the subject is treated.
- the at least two oligonucleotides which preferably are capable of hybridizing to substantially contiguous portions of the nucleic acid sequence of the subject, can optionally be administered in a pharmaceutically acceptable carrier.
- the invention provides a method of treating a subject having a proliferative disorder characterized by abnormal gene expression, comprising administering to the subject in need thereof, an effective amount of the first and second antisense oligonucleotides such that the treatment occurs.
- the invention provides a method of treating a viral infection in a subject, comprising administering to a subject in need thereof, an effective amount of first and second antisense oligonucleotides, such that the first and second antisense oligonucleotides contact a target viral nucleic acid, such that a duplex is formed, and preventing expression of a protein encoded by the target viral nucleic acid, such that treatment of the viral infection occurs.
- Figure 1 schematically depicts the hybridization of tandem anti-sense primers to target and non-target sequences.
- Figure 2 depicts melting curves of matched and mismatched sequences to a target "hairpin" sequence.
- the invention relates to anti-sense therapies, to methods for selecting anti-sense oligonucleotides for use in anti-sense therapies, and tandem anti-sense nucleotides useful in anti-sense therapies.
- antisense nucleotides As used herein, the term "antisense" nucleotides, oligonucleotides or nucleic acid are interchangeable and refer to a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule, complementary to an mRNA sequence or complementary to the coding strand of a gene.
- the invention provides a method of treating a condition related to expression of mRNA.
- the method comprises administering to a subject in need thereof an effective amount of a first anti-sense ohgonucleotide complementary to a first region of a target mRNA sequence and a second anti-sense ohgonucleotide complementary to a second region of the target mRNA sequence, the first and second anti-sense regions of the target mRNA sequence being substantially contiguous, such that the condition is treated.
- the invention provides a method for providing tandem anti-sense oligonucleotides for use in anti-sense therapy.
- the method includes the steps of selecting first and second regions of a target nucleic acid sequence, the first and second regions being substantially contiguous; and preparing first and second anti-sense oligonucleotides, the first anti-sense ohgonucleotide being complementary to the first region of the target nucleic acid sequence, and the second anti-sense ohgonucleotide being complementary to the second region of the target nucleic acid sequence, such that tandem anti-sense oligonucleotides are provided.
- tandem oligonucleotides refers to oligonucleotides which are complementary to substantially contiguous, non-overlapping sequences of target nucleic acid. Tandem oligonucleotides can include first and second antisense oligonucleotides (also referred to herein as "probes"); in certain embodiments, a third tandem ohgonucleotide (tandem to either the first or the second antisense probe), a fourth tandem ohgonucleotide, or higher numbers of oligonucleotides, can be used.
- first and second antisense oligonucleotides also referred to herein as "probes”
- a third tandem ohgonucleotide tandem to either the first or the second antisense probe
- a fourth tandem ohgonucleotide or higher numbers of oligonucleotides
- substantially contiguous refers to regions or portions of a nucleic acid which are directly adjacent to each other or are separated by no more than one intervening nucleotide base.
- tandem oligonucleotides of the present invention which bind to substantially contiguous portions of a target nucleic acid will hybridize directly adjacent to each other or separated by a gap no more than one base wide. Tandem oligonucleotides can bind cooperatively to the target nucleic acid (see, e.g. Kandlmalla et al. Nucleic Acids Rresearch (1995) 23:3578-3584).
- tandem antisense oligonucleotides are selected such that binding of a first antisense ohgonucleotide to a complementary target sequence can promote the binding of a second, tandem antisense ohgonucleotide to the target sequence.
- the first and second anti-sense oligonucleotides are selected such that the anti-sense oligonucleotides selectively bind to a target sequence which differs from non-target sequences (which are preferably not significantly bound by the antisense probes) by a single base.
- tandem anti-sense oligonucleotides permits discrimination between cells which include a native gene or mRNA and cells which include a mutant gene or mRNA, where the mutant differs from the native sequence by a single base.
- a cancerous cell in which one a single base of a gene has mutated, can be selectively targeted by appropriate choice of tandem anti-sense oligonucleotides, e.g., choice of tandem oligonucleotides which are perfectly complementary to the mutant sequence, but differ from, and do not bind significantly to, or bind less well to, the native sequence.
- the mutant cell can be targeted without significantly affecting the normal, non- target cells.
- the invention provides methods for selectively affecting a preselected target cell while not significantly affecting a non-target cell.
- the first anti-sense ohgonucleotide is 5-50 nucleotides in length, more preferably 10-25 nucleotides in length
- the second anti- sense ohgonucleotide is 5-50 nucleotides in length, more preferably 10-25 nucleotides in length, so that when they are combined the total length of tandem, anti-sense oligonucleotides bound to the target nucleic acid totals 10-105 nucleotide bases, more preferably 15-50, and most preferably 20-30 nucleotide bases.
- the ratio of the length of the first (e.g., shorter) anti- sense ohgonucleotide to the length of the second (e.g., longer) anti-sense ohgonucleotide is at least 1 :1, 1 :2, 1 :3, or 1 :4.
- the ratio of the length of the first anti-sense ohgonucleotide to the length of the second anti-sense ohgonucleotide is at least 2:1, 3: 1, or 4:1.
- the invention provides a method of treating a subject suffering from a disorder which is characterized by the presence of a mutation in a nucleic acid sequence of the subject, comprising administering to the subject in need thereof, an effective amount of at least two oligonucleotides preferentially binding to the site of the mutant nucleic acid sequence (e.g., gene or mRNA) such that the subject is treated. In such preferential binding, the anti-sense oligonucleotides are substantially contiguous.
- preferential binding refers to the selective binding of the antisense oligonucleotides to the mutant gene rather than the wild type gene.
- the invention further contemplates a method of treating diseases caused by mutations in tumor suppresser genes, e.g., P53. Mutations in proto-oncogenes can also be treated according to the methods of the invention. Certain types of mutant proto- oncogenes are known to those skilled in the art and these include, for example group c- myc, c-myb, c-fos, ras and BCR/AB.
- the invention provides a method of treating a human subject with a disorder said disorder characterized by the presence of a mutation in a nucleic acid sequence of the subject, comprising administering to the subject in need thereof in a pharmaceutically acceptable carrier, an effective amount of at least two oligonucleotides forming a duplex at the site of the mutant nucleic acid sequence (e.g., gene or mRNA), such that the subject is treated.
- a pharmaceutically acceptable carrier an effective amount of at least two oligonucleotides forming a duplex at the site of the mutant nucleic acid sequence (e.g., gene or mRNA), such that the subject is treated.
- tandem anti-sense oligonucleotides when forming a duplex are preferably substantially contiguous and are able to discriminate between the wild-type gene and the mutant gene of the subject.
- the invention provides a method of treating a human subject having a proliferative disorder which is characterized by abnormal gene expression, by administration of an effective amount of the first and second antisense oligonucleotides.
- proliferative disorders are characterized by uncontrolled proliferation of epithelial cells gut-derived epithelial cells, for example, in some colorectal cancers.
- the invention provides a method of treating a viral infection in a human subject, by administration of an effective amount of the first and second antisense oligonucleotides, binding the viral nucleic acid, forming a duplex and preventing gene expression in the virus, such that treatment occurs.
- viral targets include papillomavirus, herpes simplex virus and HIV-1.
- Sickle cell anemia is known to be caused by a single nucleic acid mutation, which results in a single amino acid substitution in hemoglobin. Persons who are heterozygous for the sickle cell trait possess one normal and one mutant gene. Therefore, treatment according to the method of the present invention, e.g., using tandem antisense oligonucleotides which are perfectly complementary to the mutant form of the gene, but which are not perfectly complementary to the normal form of the gene) can provide selective suppression of the mutant form.
- disorders characterized by the presence of a point mutation in a gene of a subject include hemophilia and Charcot-Marie-Tooth disease.
- Other diseases or conditions which can be treated according to the methods of the invention will be apparent to one of ordinary skill in the art.
- the tandem anti-sense oligonucleotides employed can preferentially "stack" onto the single base mutant RNA (the energetic difference provides for a specificity of, e.g., 10-100 fold).
- the largest energy difference between binding to a mutant (e.g., a point mutant) sequence and a native sequence will generally occur when the tandem oligonucleotides hybridize to contiguous regions of the target sequence, and the single- base change occurs at the "nick” formed by the hybridization of the tandem oligonucleotides, i.e., when a terminal base at the "nick" of one of the tandem oligonucleotides is mismatched relative to the wild-type sequence.
- the first and second anti- sense oligonucleotides are preferably selected such that the stabilization resulting from base stacking at the nick results in efficient hybridization to the pre-selected target sequence, but efficient hybridization does not occur to sequences which differ from the target sequence (for a description of base stacking energetics, see, e.g., Broude et al. (Proc. Natl. Acad. Sci. USA 91_:3072 (1994) (incorporated by reference) and references cited therein).
- tandem antisense oligonucleotides such that at least one of the tandem oligonucleotides does not stably hybridize to the target sequence in the absence of the other tandem anti-sense ohgonucleotide (e.g., the energy of base stacking at the nick is sufficient to promote efficient hybridization when both of the tandem oligonucleotides are present and hybridized to the target).
- the energetics of hybridization are dependent at least in part upon the length and base composition of the target and the anti-sense probes, as will be apparent to one of ordinary skill in the art. Accordingly, the skilled artisan will be able to select appropriate tandem anti-sense probes for a selected target sequence in light of the teachings provided herein.
- the selectivity advantage described above can be provided by designing a pair of oligonucleotides that will anneal in a tandem fashion forming a "nick” precisely at the position of a point mutation.
- the principle is illustrated in Figure 1.
- two tandem oligonucleotides (“A-S Ohgonucleotide 1 " and "A-S Ohgonucleotide 2” are shown hybridized to two contiguous regions of a target sequence ("Target", in this case a target sequence which includes a point mutant compared to the native form).
- the two anti-sense probes are perfectly complementary to the target and form a duplex with a "nick” (the two probes are not covalently joined).
- the two anti-sense oligonucleotides are not perfectly complementary to the target (in this case a native or wild-type target sequence) and a single base pair mismatch results at the site of the single base point mutation. As a result, hybridization in this case is less efficient than in Case 1. Thus, selectivity for the target sequence over the mutant sequence is achieved.
- two tandem anti-sense oligonucleotides chosen to be complementary to a mutant sequence can selective bind to a mutant target sequence, while not significantly binding to a native target sequence which differs from the mutant sequence by a single base. Accordingly, the mutant target can be selectively targeted by anti-sense therapy.
- the melting curves shown in Figures 2A-D show that for certain "imperfectly stacked" (notably an A-C and a T-C (cases C and D, Figures 2C and 2D, respectively)) an advantage is gained of ⁇ 5°C in melting temperature for the mismatched anti-sense oligonucleotides compared to the perfectly complementary tandem oligonucleotides (Case A, Figure 2A).
- the difference in melting temperature corresponds to lower stability of the mismatched oligonucleotides when the mismatched base is located at a nick between two tandem anti-sense oligonucleotides.
- the differential selectivity advantage of a two ohgonucleotide anti-sense strategy provides the ability to discriminate point mutants from native sequences.
- Exemplary (but not limiting) potential target sequences are proto-oncogenes. for example, including but not limited to the following: c-myc, c-myb, c-fos, c-kit. ras, and BCR/ABL (e.g., Wickstrom, E., Editor, "Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS", Wiley-Liss, New York, N.Y. (1991); Zalewski, A., et al., Circulation Res. 88:1 190-1 195 (1993); Calabretta, B., et al, Seminars in Cancer Biol.
- c-myc c-myb
- c-fos c-kit. ras
- BCR/ABL e.g., Wickstrom, E., Editor, "Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS", Wiley-Liss, New York, N.Y. (19
- RNA regions of the HIV- 1 protein that can be targeted by the methods of the present invention are the REV-protein response element (RRE) and the TAT-protein transactivation response element (TAR).
- RRE REV-protein response element
- TAR TAT-protein transactivation response element
- REV activity requires the presence of the REV response element (RRE), located in the HIV envelope gene (Malim. M. H., et al., Nature 338:254-257 (1989); Malim, M. H., et al., Cell 58:205-214 (1989)).
- RRE REV-protein response element
- TAR TAT-protein transactivation response element
- the tandem anti-sense oligonucleotides of the invention can be administered to a subject (including a warm-blooded animal, such as non-human mammals including dogs cats, rats, mice, sheep, cattle, horses, pigs, as well as humans) to treat a disease state related to, or caused by, expression of mRNA (or other RNA or DNA, the transcription of which can be inhibited by anti-sense oligonucleotides).
- the disease state is characterized by a single point mutation.
- the tandem anti-sense oligonucleotides can be administered together or separately, and can be administered by any appropriate route of administration (e.g., oral, intravenous, transdermal, and the like).
- the antisense ohgonucleotide molecules of the invention are typically administered to a subject or generated in situ (e.g., from a protected pro-drug form), such that they hybridize with or bind to cellular mRNA and/or genomic DNA.
- the hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix.
- An example of a route of administration of an antisense nucleic acid molecule of the invention includes direct injection at a tissue site.
- an antisense nucleic acid molecule can be modified to target selected cells and then administered systemically.
- an antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen.
- the antisense nucleic acid molecule can also be delivered to cells using the vectors described herein.
- vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.
- the antisense nucleic acid molecule of the invention is an ⁇ -anomeric nucleic acid molecule.
- An ⁇ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual ⁇ -units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641).
- the antisense nucleic acid molecule can also comprise a 2'-o- methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).
- compositions suitable for administration to a subject typically comprise the anti-sense nucleic acid molecules and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
- antibacterial agents such as benzyl alcohol or methyl parabens
- antioxidants
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., two or more anti-sense oligonucleotides) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- the active compound e.g., two or more anti-sense oligonucleotides
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova
- Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,81 1. It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- the nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors.
- Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al. (1994) PNAS 91 :3054-3057).
- the pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.
- the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
- compositions can be included in a container, pack, or dispenser together with instructions for administration.
- Anti-sense Oligonucleotides are included in a container, pack, or dispenser together with instructions for administration.
- Tandem anti-sense oligonucleotides can be designed to be complementary to any desired target sequence.
- at least one (or both) of the tandem anti-sense oligonucleotides is at least 5, 10, 15, 20, 30, 50, or 100 oligonucleotides in length.
- at least one (or both) of the tandem anti-sense oligonucleotides is not longer than about 50, 40, 30, 25, 20, 15, 10, or 5 oligonucleotides in length.
- tandem oligonucleotides can be provided in accordance with the invention.
- three, four, five or more tandem oligonucleoitdes each binding to a portion or region of a target nucleic acid sequence substantially contiguous to at least one other region to which a tandem oligonulceotide binds.
- the nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule.
- the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup B. et al. (1996) Bioorganic & Medicinal Chemistry 4 (1): 5-23).
- the terms "peptide nucleic acids” or "PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained.
- PNAs The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength.
- the synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. et al. (1996) supra; Perry-O'Keefe et al. PNAS 93 : 14670-675.
- PNAs an be used therapeutic and diagnostic applications.
- PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication.
- PNAs can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as 'artificial restriction enzymes when used in combination with other enzymes, e.g., SI nucleases (Hyrup B. (1996) supra); or as probes or primers for DNA sequence and hybridization (Hyrup B. et al. (1996) supra; Perry-O'Keefe supra).
- PNAs can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art.
- PNA-DNA chimeras can be generated which may combine the advantageous properties of PNA and DNA.
- Such chimeras allow DNA recognition enzymes, e.g., RNAse H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity.
- PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup B. (1996) supra).
- the synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. (1996) supra and Finn P.J. et al. (1996) Nucleic Acids Research 24 (17): 3357- 63.
- a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5'-(4- methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5' end of DNA (Mag, M. et al. (1989) Nucleic Acid Res. 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. et al. (1996) supra).
- modified nucleoside analogs e.g., 5'-(4- methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite
- chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. et al. ( 1975) Bioorganic Med. Chem. Lett. 5: 1 1 19-1 1124).
- the ohgonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci.
- oligonucleotides can be modified with hybridization-triggered cleavage agents (See, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988. Pharm. Res. 5:539-549).
- the ohgonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.
- An antisense ohgonucleotide can be constructed using chemical synthesis procedures known in the art.
- An antisense ohgonucleotide can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g. phosphorothioate derivatives and acridine substituted nucleotides can be used.
- modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1- methylguanine, 1 -methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2- methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5- methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D- mannosylqueosine, 5'-
- an antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., nucleic acid transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).
- Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the expression of the antisense RNA molecule in a cell of interest, for instance promoters and/or enhancers or other regulatory sequences can be chosen which direct constitutive, tissue specific or inducible expression of antisense RNA.
- the antisense expression vector is prepared as described above for recombinant expression vectors, except that the cDNA (or portion thereof) is cloned into the vector in the antisense orientation.
- the antisense expression vector can be in the form of, for example, a recombinant plasmid, phagemid or attenuated virus.
- the antisense expression vector is introduced into cells using a standard transfection technique, as described above for recombinant expression vectors.
- Another aspect of the invention pertains to methods for treating a subject, e.g., a human, having a disease or disorder characterized by (or associated with) the presence of a mutation in the genome, e.g., at least one gene or non-coding sequence of the subject. These methods include the step of administering at least two antisense oligonucleotides to the subject such that treatment occurs.
- disorders or diseases characterized by or associated with mutations in the subject genome include proliferative disorders (e.g., cancers)..
- Proliferative disorders are disorders which are associated with uncontrolled or undesirable cell proliferation.
- proliferative disorders include proliferative disorders of epithelial cells, e.g., proliferative disorders of gut derived cells, e.g., pancreatic cancer and colorectal cancer. These methods include administering to the subject an effective amount of at least two anti sense oligonucleotides such that treatment of the subject occurs.
- the terms "treating" or “treatment”, as used herein, refer to reduction or alleviation of at least one adverse effect or symptom of a disease or disorder, e.g., a disease or disorder characterized by or associated with a genetic mutation.
- modulatory methods can be performed in vitro (e.g.; by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject).
- the modulatory methods are performed in vivo, i.e., the cell is present within a subject, e.g., a mammal, e.g., a human, and the subject has a disorder or disease characterized by or associated with mutations.
- a nucleic acid molecule used in the methods of treatment can be incorporated into an appropriate pharmaceutical composition described herein and administered to the subject through a route which allows the molecule, protein, modulator etc. to perform its intended function. Examples of routes of administration are also described supra.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53699798A JP2001524942A (en) | 1997-02-24 | 1998-02-24 | Antisense oligonucleotide drugs |
EP98911409A EP1007735A1 (en) | 1997-02-24 | 1998-02-24 | Anti-sense oligonucleotide pharmacological agents |
AU65366/98A AU6536698A (en) | 1997-02-24 | 1998-02-24 | Anti-sense oligonucleotide pharmacological agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3879797P | 1997-02-24 | 1997-02-24 | |
US60/038,797 | 1997-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998037240A1 true WO1998037240A1 (en) | 1998-08-27 |
Family
ID=21901959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/003636 WO1998037240A1 (en) | 1997-02-24 | 1998-02-24 | Anti-sense oligonucleotide pharmacological agents |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1007735A1 (en) |
JP (1) | JP2001524942A (en) |
AU (1) | AU6536698A (en) |
WO (1) | WO1998037240A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005010042A1 (en) | 2003-07-18 | 2005-02-03 | Charité-Universitäts- Medezin Berlin | 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
US7704965B2 (en) | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
EP2275116A1 (en) | 2003-07-18 | 2011-01-19 | Sanofi-Aventis Deutschland GmbH | Use of a Pak inhibitor for the treatment of a joint disease |
WO2012080460A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012080461A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012080459A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012084709A1 (en) | 2010-12-17 | 2012-06-28 | Sanofi | Mirnas in joint disease |
EP2532755A1 (en) | 2011-06-10 | 2012-12-12 | Sanofi-Aventis | Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
WO2012168453A1 (en) | 2011-06-10 | 2012-12-13 | Sanofi | Methods and uses relating to the diagnosis or prognosis of pain-related tissue states or pain-related diseases such as pain |
EP2857501A1 (en) | 2013-10-03 | 2015-04-08 | ETH Zurich | Reprogramming of pluripotent stem cells for improved control of their differentiation pathways |
WO2015049277A1 (en) | 2013-10-01 | 2015-04-09 | Ruprecht-Karls-Universität Heidelberg | S100 based treatment of cardiac power failure |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
-
1998
- 1998-02-24 JP JP53699798A patent/JP2001524942A/en not_active Ceased
- 1998-02-24 AU AU65366/98A patent/AU6536698A/en not_active Abandoned
- 1998-02-24 WO PCT/US1998/003636 patent/WO1998037240A1/en not_active Application Discontinuation
- 1998-02-24 EP EP98911409A patent/EP1007735A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
Non-Patent Citations (6)
Title |
---|
DEAN N., ET AL.: "INHIBITION OF GROWTH OF HUMAN TUMOR CELL LINES IN NUDE MICE BY AN ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF PROTEIN KINASE C-ALPHA EXPRESSION.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 56., 1 August 1996 (1996-08-01), US, pages 3499 - 3507., XP002911891, ISSN: 0008-5472 * |
MAHER L. J., ET AL.: "COMPARATIVE HYBRID ARREST BY TANDEM ANTISENSE OLIGODEOXYRIBONUCLEOTIDES OR OLIGODEOXYRIBONUCLEOSDE METHYLPHOSPHONATES IN A CELL-FREE SYSTEM.", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD., GB, vol. 16., no. 08., 1 January 1988 (1988-01-01), GB, pages 3341 - 3358., XP002911888, ISSN: 0305-1048 * |
MERCOLA D., ET AL.: "ANTISENSE APPROACHES TO CANCER GENE THERAPY.", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 02., no. 01., 1 January 1995 (1995-01-01), GB, pages 47 - 59., XP002911890, ISSN: 0929-1903 * |
ODCHILD J.: "ENHANCEMENT OF RIBOZYME CATALYTIC ACTIVITY BY A CONTINUOUS OLIGODEOXYNUCLEOTIDE (FACILITATOR) AND BY 2'-O-METHYLATION.", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD., GB, vol. 20., no. 17., 1 January 1992 (1992-01-01), GB, pages 4607 - 4612., XP002911889, ISSN: 0305-1048 * |
ROBBINS & COTRAN, "Pathologic Basis of Disease", W.B. SAUNDERS COMPANY, PHILADELPHIA, 1979, pages 723-726, XP002911893 * |
SCHWAB G., ET AL.: "ANTISENSE OLIGONUCLEOTIDES ADSORBED TO POLYALKYLCYANOACRYLATE NANOPARTICLES SPECIFICALLY INHIBIT MUTATED HA-RAS-MEDIATED CELL PROLIFERATION AND TUMORIGENICITY IN NUDE MICE.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 91., 1 October 1994 (1994-10-01), US, pages 10460 - 10464., XP002911892, ISSN: 0027-8424, DOI: 10.1073/pnas.91.22.10460 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704965B2 (en) | 2002-06-26 | 2010-04-27 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
WO2005010042A1 (en) | 2003-07-18 | 2005-02-03 | Charité-Universitäts- Medezin Berlin | 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
EP2275116A1 (en) | 2003-07-18 | 2011-01-19 | Sanofi-Aventis Deutschland GmbH | Use of a Pak inhibitor for the treatment of a joint disease |
WO2012080460A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012080461A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012080459A1 (en) | 2010-12-17 | 2012-06-21 | Sanofi | Mirnas in joint disease |
WO2012084709A1 (en) | 2010-12-17 | 2012-06-28 | Sanofi | Mirnas in joint disease |
EP2532755A1 (en) | 2011-06-10 | 2012-12-12 | Sanofi-Aventis | Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
WO2012168452A1 (en) | 2011-06-10 | 2012-12-13 | Sanofi | Methods and uses based on slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain |
WO2012168453A1 (en) | 2011-06-10 | 2012-12-13 | Sanofi | Methods and uses relating to the diagnosis or prognosis of pain-related tissue states or pain-related diseases such as pain |
WO2015049277A1 (en) | 2013-10-01 | 2015-04-09 | Ruprecht-Karls-Universität Heidelberg | S100 based treatment of cardiac power failure |
EP2857501A1 (en) | 2013-10-03 | 2015-04-08 | ETH Zurich | Reprogramming of pluripotent stem cells for improved control of their differentiation pathways |
Also Published As
Publication number | Publication date |
---|---|
EP1007735A1 (en) | 2000-06-14 |
AU6536698A (en) | 1998-09-09 |
JP2001524942A (en) | 2001-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6865871B2 (en) | Includes antisense-induced exons 2 in acidic α-glucosidase | |
JP3121599B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
EP3394259B1 (en) | Compositions and methods for decreasing tau expression | |
CA2174315C (en) | Oligonucleotide modulation of multidrug resistance-associated protein | |
JP2011172597A (en) | Splice-region antisense composition and method | |
JP2002522449A (en) | 2'-O-aminoethyloxyethyl modified oligonucleotides | |
CA2079109A1 (en) | Oligonucleotide-transport agent disulfide conjugates | |
JPH11501509A (en) | Antisense transcripts associated with tumor cells having the t (14:18) translocation and oligodeoxynucleotides useful for diagnosis and treatment of these tumor cells | |
JP2005522997A (en) | Oligonucleotides containing alternating segments and uses thereof | |
US6994959B1 (en) | G-rich oligo aptamers and methods of modulating an immune response | |
WO1998037240A1 (en) | Anti-sense oligonucleotide pharmacological agents | |
US6458940B2 (en) | HPV-specific oligonucleotides | |
US6251873B1 (en) | Antisense compounds to CD14 | |
KR100353924B1 (en) | Composition and Method for Treatment of CMV Infections | |
US6429308B1 (en) | HIV infection inhibitors | |
JPH09500787A (en) | Promoting inhibition of oligonucleotides on protein production, cell growth and / or growth of infectious disease pathogens | |
MXPA01013114A (en) | Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes. | |
US5856099A (en) | Antisense compositions and methods for modulating type I interleukin-1 receptor expression | |
EP0832214A2 (en) | Oligonucleotides specific for human papillomavirus | |
DE602004008085T2 (en) | ANTISENSE OLIGONUCLEOTIDE FOR INHIBITING MELANOMA INHIBITIVE ACTIVITY (MIA) | |
EP3740500A1 (en) | Compositions and methods for increasing expression of scn2a | |
US20160272974A1 (en) | Compositions and methods for inhibiting jc virus (jcv) | |
US9932585B2 (en) | Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto | |
US6015676A (en) | Method for knocking out gene transcripts by covalently binding of an anti-sense probe | |
Tang et al. | RASONs: a novel antisense oligonucleotide therapeutic approach for asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 536997 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998911409 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998911409 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998911409 Country of ref document: EP |